 Home > Biochemistry News > Biotechnology News > Novartis Radioligand Therapy for the Treatment of Prostate Cancer Receives FDA Breakthrough Therapy Designation

Novartis Radioligand Therapy for the Treatment of Prostate Cancer Receives FDA Breakthrough Therapy Designation

 Last Update: 2021-09-07
 Source: Internet
 Author: User

Tags

jp 2 0

perimenopause hormone therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 16, 2021, Novartis announced that the US FDA has granted its potential "first-in-class" targeted radioligand therapy (radioligand therapy, RLT) 177Lu-PSMA-617 breakthrough therapy designation for Treatment of prostate specific membrane antigen (PSMA) positive castration resistant prostate cancer (mCRPC)

In recent years, radiopharmaceuticals are becoming an important direction in the field of precision tumor therapy

▲Introduction to 177Lu-PSMA-617 therapy (picture source: Novartis official website)

This breakthrough therapy designation is based on the positive results of the ongoing randomized, double-blind, open-label, multi-center Phase 3 clinical trial VISION

According to the data released at the ASCO annual meeting in 2021, the median overall survival of the patient was extended by 4 months, the risk of death was reduced by 38% (HR=0.

Note: The original text has been deleted

Reference materials:

[1] Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).

[2] FDA Grants Breakthrough Therapy Designation to 177Lu-PSMA-617 for mCRPC.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.